Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Biotechnology
- Therapeutic
- Disease
- Diagnostic
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28396
License Grant
The Licensor hereby grants to the Licensee, , a director of the Licensee, an exclusive license to make, have made, use, import, export, offer to sell, and sell Licensed Products within the Field and within the Territory provided that the Licensee retains the right to make and use the Licensed Product for non-commercial research purposes only.
License Property
The Licensor is the sole owner of the Licensed Patents regarding Natural Killer Cells.
Natural Killer Cellnatural is a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells.
Field of Use
The Licensee is a biotechnology company, developing immuno-therapeutic agents for various clinical conditions.
IPSCIO Record ID: 27427
License Grant
The Licensor, a director of the Licensee, grants the Licensee an exclusive license to make, have made, use, import, export, offer to sell, and sell Licensed Products and Technical Information within all Fields.
License Property
The Licensor is the sole owner of the Licensed Patents regarding Natural Killer Cells.
Natural Killer Cellnatural is a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells.
Field of Use
The Licensee is a biotechnology company, developing immuno-therapeutic agents for various clinical conditions.
IPSCIO Record ID: 246212
License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled “In vivo activation of natural killer cells'.
Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS
NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.â€
Field of Use
The term “Field†or “Field of Use†shall mean all applications of the Patent Rights. Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.
IPSCIO Record ID: 27682
License Grant
The Licensor grants to the Licensee a perpetual, worldwide, exclusive license, with the limited right to sublicense, under the Licensor Patents and Existing Rights, Know-How, Cell Lines, and Cell Banks; and a perpetual, worldwide, exclusive, license, without right to sublicense, under the Marks solely for the purpose of promoting, advertising, or marketing Licensee products and/or services, in the Field of in vitro and in vivo testing and diagnostic products and services.
License Property
The Licensor is a biotechnology company, developing immunotherapeutic agents for various clinical conditions and cancer.
“CONKWEST ER Cell Line†means the proprietary natural killer cell line transfected with the endoplasmic reticulum (ER) gene encoding the protein known as the KDEL motif.
“CONKWEST CI Cell Line†means the proprietary natural killer cell line transfected with the pCEP4-LTRhIL-2 vector to express endogenous interleukin-2.
“BANK Cell Bank(s)†means any GLP, cGMP, and/or GMP-certified BANK Cell Line(s).
Field of Use
The Licensee is a life sciences company specializing in the field of in vitro and in vivo testing and diagnostic products and services.
IPSCIO Record ID: 308262
License Grant
Licensors, a University and a childrens research hospital, granted the Licensee, a related party, an exclusive, royalty-bearing, worldwide license to its patent rights related to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function. The License Agreement provides the Licensee with the rights to grant and authorize sublicenses to make, have made, use, sell, offer for sale and import products and otherwise exploit the patent rights.
License Property
The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. We have engineered NKX101 to increase the cancer cell killing ability of our engineered NK cells by raising levels of NKG2D at least ten-fold as compared to non-engineered NK cells and by adding a costimulatory domain, which is an additional signaling element for white blood cells.
The two co-lead product candidates are NKX101 and NKX019. NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells
Field of Use
This agreement pertains to the drug industry relating to cell therapies to treat cancer with a method for expanding natural killer cells; a chimeric receptor and a method for supporting autonomous natural killer cell function.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
